Drug Trial Radar · NCT06636656
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Jul 30, 2027
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years. Participants visit their doctors every 4 weeks. During these visits, the doctors check the signs and symptoms of ulcerative colitis. This includes taking blood and stool samples. Doctors also do endoscopies. This is a procedure that uses a tube with a camera to look inside the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Ulcerative Colitis
Interventions
BI 3032950 intravenous (Part A)Drug
BI 3032950 intravenous (Part A)
BI 3032950 subcutaneous (Part B)Drug
BI 3032950 subcutaneous (Part B)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with clinical remission defined by the modified Mayo Score [mSC] with mSC of 0 to 2, including stool frequency subscore [SFS] of 0 or 1, rectal bleeding subscore [RBS] of 0, and centrally-read endoscopy subscore [ESS] of 0 or 1Time frame: Up to Week 12
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
One of a Kind Clinical Research Center
Scottsdale, Arizona · Not yet recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
Primary Care of Osceola
Kissimmee, Florida · Recruiting
Florida Research Institute
Lakewood Rch, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
Reliant Medical Research
Miami, Florida · Recruiting
Illinois Gastroenterology Group - Gurnee
Gurnee, Illinois · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
Columbia University Medical Center
New York, New York · Not yet recruiting
Atrium Health Gastroenterology and Hepatology
Charlotte, North Carolina · Recruiting
Texas Digestive Disease Consultants
Cedar Park, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Tyler Research Institute, LLC
Tyler, Texas · Not yet recruiting
University of Washington
Seattle, Washington · Recruiting
Digestive Health Specialists
Tacoma, Washington · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
CHC MontLegia
Liège, Belgium · Recruiting
Hepato-Gastroenterologie HK, s.r.o.
Hradec Králové, Czechia · Not yet recruiting
ISCARE a.s.
Prague, Czechia · Recruiting
Centrum Medyczne Plejady
Krakow, Poland · Recruiting
Medrise Sp. z o.o.
Lublin, Poland · Recruiting
Eskulap Pabianice Sp. z o.o.
Pabianice, Poland · Recruiting
EMC Instytut Medyczny S.A. - Poznan 70-304
Poznan, Poland · Recruiting
Clinical Research Center Sp. z o.o. Medic-R sp.k.
Poznan, Poland · Recruiting
Centrum Medyczne Medyk Sp. z o.o.
Rzeszów, Poland · Recruiting
Endoskopia Sp. z o.o.
Sopot, Poland · Recruiting
Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
Szczecin, Poland · Recruiting
Gastromed Sp. z o.o.
Torun, Poland · Recruiting
Synexus Polska Sp. z o.o.
Warsaw, Poland · Recruiting
NZOZ VIVAMED Jadwiga Miecz
Warsaw, Poland · Recruiting
Centrum Diagnostyczno Lecznicze Barska Sp. z o.o.
Włocławek, Poland · Recruiting
PlanetMed Sp. z o.o.
Wroclaw, Poland · Recruiting
EMC Instytut Medyczny S.A. - Wroclaw
Wroclaw, Poland · Recruiting
Pro Life Medica Sp. z o.o.
Zamość, Poland · Recruiting
Clinical Hospital Center Zvezdara
Belgrade, Serbia · Recruiting
Military Medical Academy
Belgrade, Serbia · Not yet recruiting
Clinical Center Zemun
Belgrade, Serbia · Not yet recruiting
General Hospital - Djordje Joanovic
Zrenjanin, Serbia · Recruiting
F D Roosevelt University General Hospital Of Banska Bystrica
Banská Bystrica, Slovakia · Recruiting
ENDOMED s.r.o.
Košice, Slovakia · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.